Media headlines about Ophthotech Corporation (NASDAQ:OPHT) have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ophthotech Corporation earned a news impact score of 0.09 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.7857598577055 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Ophthotech Corporation (NASDAQ OPHT) traded up 5.10% during midday trading on Monday, reaching $2.68. The company had a trading volume of 623,292 shares. The company’s market capitalization is $96.32 million. The firm’s 50 day moving average price is $2.62 and its 200-day moving average price is $3.15. Ophthotech Corporation has a 12 month low of $2.24 and a 12 month high of $59.99.

Ophthotech Corporation (NASDAQ:OPHT) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.45. The company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $1.38 million. During the same period last year, the company earned ($0.85) earnings per share. Ophthotech Corporation’s revenue for the quarter was down 94.1% compared to the same quarter last year. Analysts anticipate that Ophthotech Corporation will post $0.29 earnings per share for the current fiscal year.

Separately, Zacks Investment Research upgraded Ophthotech Corporation from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research report on Tuesday, May 2nd. Twelve investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Ophthotech Corporation currently has a consensus rating of “Hold” and an average price target of $54.47.

ILLEGAL ACTIVITY WARNING: “Ophthotech Corporation (OPHT) Earns Media Impact Rating of 0.09” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/14/ophthotech-corporation-opht-earns-media-impact-rating-of-0-09.html.

In related news, Chairman David R. Guyer sold 17,678 shares of the stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $2.58, for a total value of $45,609.24. Following the transaction, the chairman now directly owns 37,692 shares in the company, valued at $97,245.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 34,609 shares of company stock worth $89,249 over the last three months. 2.00% of the stock is owned by insiders.

About Ophthotech Corporation

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech Corporation (NASDAQ:OPHT)

Receive News & Stock Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related stocks with our FREE daily email newsletter.